Discovery of (2-(pyrrolidin-1-yl)thieno[3,2-d]pyrimidin-4-yl)(3,4,5-trimethoxyphenyl)methanone as a novel potent tubulin depolymerizing and vascular disrupting agent

Eur J Med Chem. 2022 Aug 5:238:114466. doi: 10.1016/j.ejmech.2022.114466. Epub 2022 May 17.

Abstract

In this study, a series of 2-substituted thieno[3,2-d]pyrimidin-4-yl(3,4,5-trimethoxyphenyl)methanones were designed, synthesized and evaluated as novel anti-tubulin polymerization and vascular disrupting agents. A pyrrolidin-1-yl derivative, compound 20, exhibited strong antiproliferative activities (average IC50 = 13.4 nM) against four cancer cell lines. 20 also showed retained potency toward paclitaxel-resistant A549 cells. 20 could significantly inhibit tubulin polymerization with an IC50 of 1.6 μM. 20 displayed strong induction of G2/M arrest and apoptosis through the mitochondrial pathway. Dose-dependent suppression of the migration of cancer cells and the formation of a vascular network were observed after treatment with 20. The acceptable microsomal stability implied that it is worth conducting further study on the analogues of 20 as novel drug candidates of CBSIs.

Keywords: Anti-tubulin polymerization; G2/M arrest; Induction of apoptosis; PTX-resistant A549; Vascular disrupting agent.

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Apoptosis
  • Cell Line, Tumor
  • Cell Proliferation
  • Drug Screening Assays, Antitumor
  • G2 Phase Cell Cycle Checkpoints
  • Humans
  • Polymerization
  • Structure-Activity Relationship
  • Tubulin Modulators / pharmacology
  • Tubulin* / metabolism

Substances

  • Antineoplastic Agents
  • Tubulin
  • Tubulin Modulators